Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189419 | 1.00 | RORC (0.44) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL2677957 | 1.00 | RORC (0.44) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL4752713 | 1.00 | RORC (0.44) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL30881248 | 0.86 | MAPT (0.44) | RORCGPR119USP30HDAC1STS | |
| SCHEMBL4762180 | 0.83 | PDE4B (0.49) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL1014011 | 0.83 | PDE4B (0.49) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL1014009 | 0.83 | PDE4B (0.49) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL4762175 | 0.83 | PDE4B (0.49) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL1014994 | 0.83 | PDE4B (0.49) | RORCGPR119NAMPTUSP30KDM4E | |
| SCHEMBL3181295 | 0.78 | NR1H2 (0.44) | RORCNAMPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| EP-1539783-B1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | EINSTEIN COLL MED (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
| US-20060160765-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | RORC 1103/4885GPR119 3510/4885NAMPT 14/4885 |
| US-20060160765-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | PNP, MTAP, TYMP | RORC 1635/4885GPR119 3418/4885NAMPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.